HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marschall, H.-U. Articles by Matern, S. Search for Related Content PubMed PubMed Citation Articles by Marschall, H.-U. Articles by Matern, S. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 42, 735-742, May 2001
Copyright © 2001 by Lipid Research, Inc.

Original Article

Isoursodeoxycholic acid: metabolism and therapeutic effects in primary biliary cirrhosis

Correspondence to: Hanns-Ulrich Marschall, To whom correspondence should be addressed., hanns-ulrich.marschall{at}mbb.ki.se (E-mail)

Significant amounts of ursodeoxycholic acid (UDCA) used for the treatment of patients with primary biliary cirrhosis (PBC) become epimerized at C-3 to isoUDCA. We investigated the metabolism of isoUDCA and a possible pharmacologic effect in five patients (51.4 ± 5.8 years old; 3 females, 2 males) with PBC and persistent elevations of -glutamyl transpeptidase (-GT) and alkaline phosphatase despite treatment with UDCA for more than one year. Serum samples were analyzed for bile acid metabolites and surrogate markers of cholestasis in 4-week intervals after 1 g/d UDCA, wash-out, 0.5 g/d isoUDCA, 0.75 g/d isoUDCA, 0.75 g/d UDCA, and two further periods with 1 g/d UDCA. Bile acids in urine were analyzed after wash-out, 0.5 and 0.75 g/d isoUDCA, and 0.75 and 1 g/d UDCA. During wash-out, AST, AP, and -GT rose significantly (P < 0.05) but reversed to previous levels during the first isoUDCA period, with 0.5 g/d only. No further improvements were observed after increasing the dose of isoUDCA or switching back to UDCA. In serum, the relative amounts of isoUDCA and UDCA were 8.1 ± 7.4% and 16.2 ± 6.4% during 0.5 g/d isoUDCA, 6.2 ± 2.5% and 45.0 ± 4.1% during 0.75 g/d isoUDCA, and 0.5;–3% and 56.4;–60.0%, respectively, during UDCA. In urine, UDCA was the predominant bile acid both during isoUDCA and UDCA medications. The similar serum enrichment and urinary excretion of UDCA during administration of either isoUDCA or UDCA together with low concentrations of the intermediate of isomerization, 3-dehydro-UDCA, indicate a first-pass epimerization of isoUDCA to UDCA in the liver. Approximately 25% of serum isoUDCA and 10% of serum UDCA were conjugated with either glucuronic acid or N-acetylglucosamine, indicating hepatic formation and systemic secretion of glycosidic conjugates.

In PBC patients, isoUDCA becomes isomerized to UDCA and has similar effects on surrogate markers of cholestasis. Thus, isoUDCA has pro-drug characteristics.—Marschall, H-U., U. Broomé, C. Einarsson, G. Alvelius, H. G. Thomas, and S. Matern. Isoursodeoxycholic acid: metabolism and therapeutic effects in primary biliary cirrhosis. J. Lipid Res. 2001. 42: 735–742.

Supplementary key words: ursodeoxycholic acid, bile acid metabolis, N-acetylglucosaminidation, glucosidation, glucuronidation, gas chromatography-mass spectrometry, electrospray mass spectrometry

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. P. Hamilton, G. Xie, J.-P. Raufman, S. Hogan, T. L. Griffin, C. A. Packard, D. A. Chatfield, L. R. Hagey, J. H. Steinbach, and A. F. Hofmann Human cecal bile acids: concentration and spectrum Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G256 - G263. [Abstract] [Full Text] [PDF]

				H.-U. Marschall, M. Wagner, K. Bodin, G. Zollner, P. Fickert, J. Gumhold, D. Silbert, A. Fuchsbichler, J. Sjovall, and M. Trauner Fxr-/- mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids J. Lipid Res., March 1, 2006; 47(3): 582 - 592. [Abstract] [Full Text] [PDF]